Dr. Efrat Dotan, MD
Medical Oncology (Medical Oncology Physician)
333 Cottman Avenue, Fox Chase Cancer Center
Philadelphia, PA 19111
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 93
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
PA license MD433159 -
Internal Medicine Physician
PA license MD433159
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Lancaster General Hospital Lancaster, PA
Medical groups
- Lancaster General Medical Group (586 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 93
- Services billed
- 343
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 316 | 118 |
| Established patient office or other outpatient visit, 40-54 minutes | 202 | 80 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 29 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 22 | 11 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 21 | 12 |
| Established patient office or other outpatient visit, 20-29 minutes | 19 | 17 |
| New patient office or other outpatient visit, 45-59 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Philadelphia, PA | 20 |
| Prochlorperazine Maleate Other prescribers in Philadelphia, PA | 14 |
| Atenolol Other prescribers in Philadelphia, PA | 13 |
| Ondansetron Hcl Other prescribers in Philadelphia, PA | 13 |
| Pantoprazole Sodium Other prescribers in Philadelphia, PA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 6 payments worth $8,455 in total to this clinician.
| AbbVie Inc. | $3,650 |
|---|---|
| Amgen Inc. | $2,744 |
| Jazz Pharmaceuticals Inc. | $2,040 |
| Lilly USA, LLC | $20.95 |
| Consulting Fee | $8,409 |
|---|---|
| Food and Beverage | $45.95 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Jun 11, 2025 | Consulting Fee | $3,625 |
| Amgen Inc. May 28, 2025 | Consulting Fee | $2,744 |
| Jazz Pharmaceuticals Inc. Nov 7, 2025 | Consulting Fee ZIIHERA · HEMATOLOGY/ONCOLOGY | $1,530 |
| Jazz Pharmaceuticals Inc. Jun 25, 2025 | Consulting Fee ZIIHERA · HEMATOLOGY/ONCOLOGY | $510 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $53,397 in research payments for these studies, mostly to the institutions running them.
- Phase 2/3 BMS-986504+Gemcitabine/Abraxane vs Gemcitabine/Abraxane in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
E.r. Squibb & Sons, L.l.c. - Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
Beigene, Ltd. · Completed · NCT03777657 - A phase 2B3 randomized doubleblind study to investigate the efficacy safety and tolerability of ponsegromab PF06946860 compared with placebo both with background firstline chemotherapy in adult participants with cache…
Pfizer Inc. - A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06855771
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.